Hims & Hers Health announced a new agreement with Eli Lilly allowing patients to purchase the drugmaker’s GLP-1 medications directly through its platform. Previously, participants in Hims’ weight-loss program who wanted to use Zepbound or Foundayo were directed to Lilly’s telehealth platform to buy the medication. Hims also said it would not compound GLP-1 medications such as Zepbound in the future. Hims & Hers stock is rallying following the announcement.
Source: Read the original article
Disclaimer: this content is for information purposes only and is not financial advice. Cryptocurrencies are highly volatile: you may lose all of your capital. Always do your own research. Legal notice
